CA
LCTX icon

Crewe Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Crewe Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,016
Closed -$1.01K – 863
2024
Q2 		$1.01K Hold
1,016
– – ﹤0.01% 894
2024
Q1 		$1.5K Buy
+1,016
New +$1.15K ﹤0.01% 865

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Crewe Advisors's LCTX Position: Q3 2024 in Review

Crewe Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2024, closing a stake of 1,016 shares — an estimated $1.01K sold.

Crewe Advisors first reported a position in LCTX in Q1 2024 and held it in 2 quarters. The position peaked at $1.5K in Q1 2024. 114 funds tracked by Wall St. Rank hold LCTX as of Q3 2024.

  • Crewe Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Crewe Advisors sold 1,016 Lineage Cell Therapeutics shares in Q3 2024, an estimated $1.01K.
  • Crewe Advisors first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 2 quarters.
  • Crewe Advisors's Lineage Cell Therapeutics position peaked at $1.5K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2024.

Based on Crewe Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.